. 2021 May 14;100(19):e25923. doi: 10.1097/MD.0000000000025923

Table 1.

XXXX.

	Comorbidities	Other treatments	ETI/NIV	CRP (mg/dl)			LDH (U/L)			CPK (U/L)			Ferritin (μg/L)			D-Dimer (ng/mL)			Outcome (x10⁹/L)	IL-6 (pg/mL)			Limphocytes
				a	b	c	a	b	c	a	b	c	a	b	c	a	b	c		a	b	c
P1: W, 76y	HTN, DMII, AF	lopinavir/ritonavir^a	ETI	68	153	18	293	309	247	46	44	27	302	442	348	774			124,9	0,37	0,90	1,35	Discharged home 22 days after sarilumab
		hydroxychloroquine plus azithromycin^b^,^∗∗
P2: W, 71y	HTN, DMII	hydroxychloroquine plus azithromycin^b	NIV	221	330	15	608	528	292	424	159		3771	2529			2272	2036	–	0,97	0,89	1,76	Discharged home 19 days after sarilumab
P3: M, 78y	HTN, COPD, AF, Obesity	hydroxychloroquine plus azithromycin^b	NIV	143	152	208	287	398	435	869	179	151	1198		3394		302	515	380	0,64	0,47	0,57	Death 2 days. after sarilumab
P4: W, 79y	HTN, DLP CKDIIIa,	hydroxychloroquine plus azithromycin^b	NIV	400	480			766	713		160			319			83275	31975	65,2		0,71	0,45	Death 6days after sarilumab
		prednisolone 250 mg^c
P5: M, 62y	HTN, DMII, hepatic fibrosis	hydroxychloroquine plus azithromycin^b	NIV	76	123	25	331	334	221				326	581	461	727	856	1546	98,7	1,29	1,72	1,98	FiO₂₍21%) 9 days after sarilumab

AF = atrial fibrillation, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, DLP = dyslipidemia, DM = diabetes mellitus, ETI = endotracheal intubation, HTN = hypertension, NIV = non invasive ventilation.

At admission.

Before sarilumab.

After sarilumab.

^∗∗

Hydrochloroquine 400 mg/12h (1d) followed by 200 mg/12h (4 more days) plus azithromycin 500 mg/d (3 days).